Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4191 Hypercalcemia due to parathyroid hormone-related protein (PTHrP) secretion in pNETs: A series of cases

Introduction: Hypercalcemia (HC) by parathyroid hormone related protein (PTHrP) in pancreatic neuroendocrine tumors (pNETs) are rare.

Conference:

Presenting Author:

Authors: Peiró I, Guerrero-Pérez F, Teulè A, Balsa M, Ruffinelli J,

Keywords: Pancreatic neuroendocrine tumor, malignant hypercalcemia, PTHrP,

#4015 Responses to Cabozantinib plus Atezolizumab in a wide population of advanced and progressive neuroendocrine neoplasms (NENs): A prospective multi-cohort basket phase II Trial (CABATEN / GETNE-T1914)

Introduction: Angiogenesis plays a key role in development and progression of NENs and synergism has been observed when combined with immune-checkpoint inhibitors in other tumors.

Conference:

Presenting Author: Molina-Cerrillo J

Authors: Molina-Cerrillo J, Grande E, Benavent M, Garcia-Carbonero R, Teule A,

Keywords: neuroendocrine neoplasm, Cabozantinib, Atezolizumab, CABATEN, prospective multi-cohort Basket Phase II Trial,

#3838 Subgroup analysis of ORR and PFS of the SEQTOR study (GETNE 1206) – Everolimus followed by Streptozotocin (STZ)-5FU upon progression or the reverse sequence, in advanced progressive panNETs

Introduction: Previous global results of ORR and PFS1 have been presented. The best treatment (Tx) sequence between STZ-5FU and everolimus (EVE) in patients (pts) with advanced and progressive panNETs is not yet well established.

Conference:

Presenting Author: Salazar R

Authors: Capdevila J, Tafuto S, Krogh M, Teulé A, Garcia-Carbonero R,

Keywords: panNET, everolimus, STZ-5FU,

#3569 Outcomes of Streptozotocin (STZ)-based chemotherapy (CT) in patients with advanced pancreatic neuroendocrine tumors (pNETs): Data from the Spanish Taskforce of Neuroendocrine and Endocrine Tumors (GETNE) national registry (R-GETNE)

Introduction: STZ-based CT has been used for advanced pNETs with rapid growth, high tumor load or progression to somatostatin analogues (SSA). Evidence supporting use of STZ-based CT in pNET is mainly retrospective, and there is an unmet need of prospective trials in this setting. We present data from the R-GETNE regarding the use of STZ in spanish centers.

Conference:

Presenting Author:

Authors: Esteban-Villarrubia J, Hernando J, Garcia A, Jimenez-Fonseca P, Teulé A,

Keywords: Streptozotocin, Chemotherapy, pNET, GETNE, R-GETNE,

#3550 Randomized open label phase III study comparing the efficacy and safety of Everolimus followed by chemotherapy with Streptozotocin (STZ)-5FU upon progression or the reverse sequence, in advanced progressive panNETs: The SEQTOR study (GETNE 1206)

Introduction: STZ-5FU and everolimus are frontline options for systemic treatment in patients with advanced and progressive pancreatic neuroendocrine tumors (panNETs). Switch between both upon progression is a common strategy, but the best sequence is not yet well established.

Conference:

Presenting Author: Salazar R

Authors: Capdevila J, Tafuto S, Vestermark L, Teulé A, Garcia-Carbonero R,

Keywords: pNET, everolimus, streptozotocin, 5FU, randomized trial,